BioCentury | Jan 12, 2021
Deals

Jan. 11 Quick Takes: Inmagene gains options to four Chi-Med immunology programs; plus Zai-Turning Point, Mirati-Resolution, GSK-Eligo, Biogen-Apple, Adaptive-AZ and more

Chi-Med, Inmagene partner on immunological indicationsHutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) granted Inmagene Biopharmaceuticals Co. Ltd. exclusive options to four immunological diseases programs for up to $95 million in development milestones, $135 million in commercial...
BioCentury | Jan 12, 2021
Emerging Company Profile

Atalanta’s next-gen RNAi branches deeper into brain, hooks Biogen and Genentech

A rush of interest following the publication of Atalanta’s brain-optimized siRNA tech enabled the UMass Medical School spinout to launch with two high-profile partners in hand. Atalanta Therapeutics Inc....
BioCentury | Dec 31, 2020
Distillery Therapeutics

Combining cholesterol metabolism inhibition with T cell therapy for glioblastoma, melanoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer; melanoma Tethering T cell therapies to an inhibitor of the cholesterol metabolism enzyme SOAT could enhance the cell therapy’s efficacy against glioblastoma and melanoma. The T cells were engineered...
BioCentury | Dec 31, 2020
Regulation

Dec. 30 Quick Takes: A first for Chi-Med; plus Orphazyme, BMS, FDA REMS, Pfizer, Astellas, Alkermes, Osmotica, Quanterix, Ampio and Novartis

Chi-Med’s surufatinib approved in ChinaChina’s National Medical Products Administration (NMPA) approved an NDA from Hutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) for Sulanda surufatinib to treat non-pancreatic neuroendocrine tumors. The FGFR, VEGFR and CSF1R inhibitor is...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Oligodendrocyte-derived extracellular vesicles for multiple sclerosis

DISEASE CATEGORY: Autoimmune disease INDICATION: Multiple sclerosis (MS) Extracellular vesicles derived from oligodendrocytes could prevent and treat MS. The vesicles were collected from the supernatant of mature oligodendrocytes differentiated from mouse oligodendrocyte progenitor cells. In mouse models...
BioCentury | Nov 19, 2020
Finance

Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more

Elevation raises $65M series B, names Leland CEOElevation Oncology Inc. raised $65 million in a series B round and promoted founder Shawn Leland from CBO to CEO. The venture round was led by venBio Partners and Cormorant...
BioCentury | Nov 19, 2020
Finance

With $4.6B fund to spend, Blackstone branching beyond Clarus’ ‘bread and butter’ risk-sharing deals

Two years after Clarus’ acquisition by Blackstone, the life sciences investor is taking advantage of its parent company’s scale to stretch beyond its initial sweet spot. The firm that specialized in risk-sharing deals is now...
BioCentury | Nov 17, 2020
Product Development

Moderna times & China’s future: a BioCentury podcast

Now that Moderna and partners BioNTech and Pfizer have set the bar for efficacy in COVID-19 vaccines, what’s next for the rest of players in the hunt? On the latest edition of the BioCentury This...
BioCentury | Nov 14, 2020
Deals

Innovation in a hurry: China biotechs see a fast track to global stage – survey

The Chinese biopharma landscape in five years will see a majority of the money magnet companies commanding innovation, with first-in-class targets filling their pipelines and innovative biologics outpacing...
BioCentury | Oct 31, 2020
Distillery Therapeutics

Blocking ROR2 for osteoarthritis

DISEASE CATEGORY: Musculoskeletal INDICATION: Osteoarthritis Inhibiting the tyrosine protein kinase receptor ROR2 could treat osteoarthritis. Expression levels of the ROR2 ligand WNT5A were higher in human osteoarthritic cartilage than in healthy cartilage. In a mouse fibroblast...
Items per page:
1 - 10 of 4205
BioCentury | Jan 12, 2021
Deals

Jan. 11 Quick Takes: Inmagene gains options to four Chi-Med immunology programs; plus Zai-Turning Point, Mirati-Resolution, GSK-Eligo, Biogen-Apple, Adaptive-AZ and more

Chi-Med, Inmagene partner on immunological indicationsHutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) granted Inmagene Biopharmaceuticals Co. Ltd. exclusive options to four immunological diseases programs for up to $95 million in development milestones, $135 million in commercial...
BioCentury | Jan 12, 2021
Emerging Company Profile

Atalanta’s next-gen RNAi branches deeper into brain, hooks Biogen and Genentech

A rush of interest following the publication of Atalanta’s brain-optimized siRNA tech enabled the UMass Medical School spinout to launch with two high-profile partners in hand. Atalanta Therapeutics Inc....
BioCentury | Dec 31, 2020
Distillery Therapeutics

Combining cholesterol metabolism inhibition with T cell therapy for glioblastoma, melanoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer; melanoma Tethering T cell therapies to an inhibitor of the cholesterol metabolism enzyme SOAT could enhance the cell therapy’s efficacy against glioblastoma and melanoma. The T cells were engineered...
BioCentury | Dec 31, 2020
Regulation

Dec. 30 Quick Takes: A first for Chi-Med; plus Orphazyme, BMS, FDA REMS, Pfizer, Astellas, Alkermes, Osmotica, Quanterix, Ampio and Novartis

Chi-Med’s surufatinib approved in ChinaChina’s National Medical Products Administration (NMPA) approved an NDA from Hutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) for Sulanda surufatinib to treat non-pancreatic neuroendocrine tumors. The FGFR, VEGFR and CSF1R inhibitor is...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Oligodendrocyte-derived extracellular vesicles for multiple sclerosis

DISEASE CATEGORY: Autoimmune disease INDICATION: Multiple sclerosis (MS) Extracellular vesicles derived from oligodendrocytes could prevent and treat MS. The vesicles were collected from the supernatant of mature oligodendrocytes differentiated from mouse oligodendrocyte progenitor cells. In mouse models...
BioCentury | Nov 19, 2020
Finance

Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more

Elevation raises $65M series B, names Leland CEOElevation Oncology Inc. raised $65 million in a series B round and promoted founder Shawn Leland from CBO to CEO. The venture round was led by venBio Partners and Cormorant...
BioCentury | Nov 19, 2020
Finance

With $4.6B fund to spend, Blackstone branching beyond Clarus’ ‘bread and butter’ risk-sharing deals

Two years after Clarus’ acquisition by Blackstone, the life sciences investor is taking advantage of its parent company’s scale to stretch beyond its initial sweet spot. The firm that specialized in risk-sharing deals is now...
BioCentury | Nov 17, 2020
Product Development

Moderna times & China’s future: a BioCentury podcast

Now that Moderna and partners BioNTech and Pfizer have set the bar for efficacy in COVID-19 vaccines, what’s next for the rest of players in the hunt? On the latest edition of the BioCentury This...
BioCentury | Nov 14, 2020
Deals

Innovation in a hurry: China biotechs see a fast track to global stage – survey

The Chinese biopharma landscape in five years will see a majority of the money magnet companies commanding innovation, with first-in-class targets filling their pipelines and innovative biologics outpacing...
BioCentury | Oct 31, 2020
Distillery Therapeutics

Blocking ROR2 for osteoarthritis

DISEASE CATEGORY: Musculoskeletal INDICATION: Osteoarthritis Inhibiting the tyrosine protein kinase receptor ROR2 could treat osteoarthritis. Expression levels of the ROR2 ligand WNT5A were higher in human osteoarthritic cartilage than in healthy cartilage. In a mouse fibroblast...
Items per page:
1 - 10 of 4205